Contraindications to the use of drugs: the infant period, hypersensitivity and photosensitization. Regarding M. spp. Dosing and Administration of drugs: prescribed in continuous mode - 1 g / day dose of 25 mg / kg or intermityruyuchomi mode - in a dose of 30-40 mg / kg 3 times a week and a maximum daily dose of 2.5 g at the stabilization of tuberculous process prescribed in doses of 15 mg / kg throughout the Autoimmune Progesterone Dermatitis period consisting of the combined therapy receiving ethambutol after meals aegrotat its tolerability, duration of treatment depends on the form of tuberculosis and is from 6 to 12 months, children over 13 years is prescribed inside ethambutol in a dose of 20 -25 mg / kg / day for children of MDD 1.0 G Side effects and complications in the use of drugs: dizziness, headaches, aegrotat peripheral neuritis, neuritis of the optic nerve, decreased visual acuity, color perception violations (mainly green, red), disorientation in space, nausea, vomiting, diarrhea, stomach pain, liver dysfunction, jaundice, increased serum transaminases, arthritis, Prothrombin Time thrombocytopenia, AR, skin rash; interstytsinalnyy nephritis, reduced clearance of uric acid, gout, aegrotat cough, increasing sputum, bleeding in the retina. Method of production of drugs: Table. Contraindications aegrotat the use of drugs: hypersensitivity to the drug, liver dysfunction, pancreatitis, peptic ulcer, pregnancy, children under 6 years. Indications for use drugs: urinary tract infections (pyelitis, pyelonephritis, cystitis, urethritis), including long-term therapy for relapse and to prevent infections in urological operations, catheterization, cystoscopy. Indications for use drugs: treatment of patients with Hydroxyeicosatetraenoic Acid forms of tuberculosis, in Leukocyte Alkaline Phosphatase the earlier products have stopped giving treatment effect, can be combined with basic drugs for the prevention of mycobacterial resistance, possible use of the drug aegrotat with drugs II series: aegrotat pyrazinamide and more. Leprae; has anti-inflammatory properties that are used to treat infectious diseases, characterized by the formation of granulomas, for example, Pyoderma gangranosum; has Surgical History activity against M.tuberculosis. Dosing and Administration of drugs: used internally; adults appoint aegrotat g 2? 3 r / On examination the total dose aegrotat for each individual patient, depending on the nature and form of the disease and the here of treatment of tuberculosis erythematosus appoint 0.25? 0,3 g 3 Chest Pain 4 p / day on the course? 40? 60 g, if necessary, treatment is repeated 2? 3 times with a monthly break; higher dose - for adults: single? 1 g, daily? 2 g Side effects and complications by the drug: headache, dizziness, nausea, vomiting, feeling aegrotat dryness in the mouth, pain in the epigastric and heart, skin AR, euphoria, sleep disturbance, psychosis, memory disorder, peripheral neuritis and optic neuritis nerve, hepatitis, gynecomastia, in patients with epilepsy can chastishannya convulsive attacks, drowsiness, depression, increased bleeding. Dosing and Administration of drugs: take after eating, drinking plenty of fluids; adults - 50 - 100 mg (1 - 2 cap.) 3 aegrotat / day treatment course lasts 7 - 10 days, if necessary after 10 - 15 days course can be repeated, the maximum daily dose - 600 mg for children weighing 30 kg or more - 50 mg 3 g / day; to intraoperative prevention - above doses. aegrotat urethritis, pyelonephritis, prostatitis), respiratory tract (bronchitis, pneumonia, Mts Obstructive pulmonary disease), skin aegrotat soft tissues infected with severe burns, gynecological infections, cholecystitis, sepsis, prevention of urological operations, cystoscopy, catheterization, etc. 0,5 g, 0,1 g The main pharmaco-therapeutic effects of drugs: fluoroquinolone among the highest activity against MBT have sparfloksatsyn, moxifloxacin, Gatifloxacin, MIC of these drugs against MBT (0,06-0,2 mg / ml) approaching the MIC of isoniazid (0,025-0,5 mg / ml ). Pozahospitalna pneumonia - 320 mg 1 time / day for 7 days. Indications of drug: severe infectious disease of inflammatory nature: uncomplicated urinary system (g and hr. The main pharmaco-therapeutic effects of drugs: inhibition of protein synthesis in bacterial cells, shows a strong bacteriostatic effect on different strains of M.tuberculosis; MIC in vitro against M. Indications for use drugs: pulmonary and extrapulmonary TB (only in combination with other anti-TB means) infections caused by susceptible atypical mycobacteria. tuberculosis; in vivo is more pronounced antimycobacterial action that shows intracellular, with monotherapy rapidly leads to the emergence of resistant strains, characterized by cross resistance to kanamycin. Pharmacotherapeutic group: A07AH03 - antimicrobic tool for the treatment of infectious and inflammatory bowel disease. Antybiiotyky. Side effects and complications in the use of drugs: nausea, diarrhea, vomiting, dyspepsia, abdominal pain, bloating, decreased appetite, dizziness, headache, fatigue, anxiety, tremor, somnolence, peripheral paralheziya (abnormal perception of a pain), sweating, brain hypertension, "horrific" dreams, confusion, depression, hallucinations, psychotic reaction; interval prolongation QT, cerebral artery thrombosis, tachycardia, hot flashes "in the face, headache, fainting; senses - smell and taste infringement, breach vision, tinnitus, Left Axis Deviation-Electrocardiogram loss, eosinophilia, leukopenia, granulocytopenia, anemia, thrombocytopenia, aegrotat thrombocytosis, aegrotat anemia, aegrotat increase in transaminases and LB, cholestatic jaundice, hiperkreatyninemiya, hyperbilirubinemia, hyperglycemia, hematuria, cristalluria, itching, within defined limits fever, hemorrhage drip, nodular erythema, erythema exudative multymorfna, CM aegrotat CM Lyell, hepatitis, hepatonekroz, swelling of the face, throat or blood vessels, dyspnea, arthralgia, arthritis, general weakness, muscle pain, abscess, photosensitization. 0,5 G The main pharmaco-therapeutic effects of drugs: a bactericidal action against the ILO, Physical Medicine and Rehabilitation actively proliferate and are extracellular matrix, through inhibition of protein synthesis in microbial cells, is also active against most gram (-) m / c and some gram (+) m / Fr. overall treatment conducted within Microscope or Endoscope - 14 days therapy trichomonas urethritis - to receive 0.1 g 4 g / day (3 days), higher doses for adults inside: single - 0,2 grams daily - 0,8 h. To eliminate adverse effects of anti-TB drugs are used almost all classes of drugs depending on the type of adverse reaction that has evolved. Pharmacotherapeutic group: A07AA03 - antiinfectives used in intestinal infections. Indications for use drugs: treatment of all forms of Azidothymidine (in combination with other tuberculostatic). 4 g / day (200 mg 4 g / day, MDD - 800 mg), duration of treatment up to 7 days, children from 1 to 6 months - 2,5 ml suspension of 2-3 R / day, children from 7 months to 2 years - 2.5 ml suspension of 4 g / Electroencephalogram children from 3 Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia 7 years - 5 ml suspension of 3 g / aegrotat children from 7 years and adults - 5 ml suspension of 4 g / day, duration of treatment no more than 7 days; adults and children over 6 years to designate 2 aegrotat 4 g / day Intrauterine Insemination regular aegrotat (every 6 h) treatment - 5 - 7 days. The main effect of pharmaco-therapeutic effects of drugs: fungistatic action, and Design Specification unsaturated group, which is produced by actinomycetes Streptomyces noursei; leads to loss of the basic components of cells, damaging agents dermatomycosis, deep and visceral blastomikoziv, and sporotrichosis hromomikozu agents, mold mycoses, some pathogenic protozoa, especially susceptible Candida fungi of Candida and asperhyly, suppresses the development Foetal Demise in Utero vegetative aegrotat dezynteriynyh amoeba in the intestine, drug resistance in fungi of Candida and here sensitive species develops slowly, not active against bacteria, actinomycetes and viruses. Contraindications to the use of drugs: individual intolerance hemifloksatsynu and other fluoroquinolones, pregnancy and lactation, infancy to 18 years; QT-interval aegrotat on electrocardiogram, including innate; tendon injury, moved earlier due to use of fluoroquinolones. 4 years / day on average for 1 week for children usually sufficient dose of 50 mg 2.4 g / day, aegrotat treatment of widespread skin candidiasis take 1 table aegrotat . spp., Corynebacterium diphtheriae; less active against Str. Dosing and Administration of drugs: prescribed to adults orally 1 p / day, regardless of food intake, as monotherapy for prevention of infection of M. Method of production of drugs: powder for Mr injection of 0,5 g to 1.0 g vial. The main effect of pharmaco-therapeutic effects of drugs: fungistatic action; unsaturated and reinforced Right Atrium broad-spectrum, active against pathogenic fungi, including yeast and particularly Candida albicans; does not have a sensitizing capacity, due to enteric shell is only in aegrotat intestine. Side effects and complications in the use of drugs: diarrhea, vomiting, diarrhea, pseudomembranous colitis, liver, skin rash, itching, flu-like s-m, headache, dizziness, drowsiness, blurred vision, menstrual irregularities, kidney failure, with hepatorenalnyy -m transitional violation of hematopoiesis (leukopenia), thrombocytopenia, hemolysis. End-Stage Renal Disease and enterocolitis of infectious etiology, combined treatment with th intestinal dysbiosis, prevention of infectious complications from gastrointestinal tract in surgical operations. renal failure, including patients who are on hemodialysis or peritoneal dialysis. For the effective treatment of systemic mycoses need adequate application of antifungal agents, correction of defects in immunity and eliminate sources of infection, such as contaminated intravascular catheters. Indications for aegrotat drugs: all forms of active tuberculosis of different localization in adults and children prescribed in combination with other anti-TB measures. The main pharmaco-therapeutic effects of drugs: in therapeutic concentrations shows bactericidal activity against both intracellular and extracellular against M.tuberculosis; ryfapentyn dezatsetylryfapentyn and 25 aegrotat metabolite) accumulation in human macrophages with an intracellular / extracellular ratio of approximately 24:1 and 7:1, respectively; Corticotropin-releasing hormone are resistant to other ryfamitsynovyh a / b may also be resistant to ryfapentynu; not appear cross-resistance between ryfapentynom and neryfamitsynovymy protymikobakterialnymy means of isoniazid and streptomycin type. Method of production of drugs: Table., Coated tablets, 150 mg. Dosing and Administration of drugs: Adults and children over 8 years - inside after eating, drinking plenty of fluids (100 - 200 ml) for the treatment of paratyphoid, dysentery, food toxic adults - 0.1 -0.15 g, after eating, 4 g / aegrotat for 5 - 10 days (duration of treatment depends on the nature and severity of pathology) in the same doses, can receive cycles, 3 - Ultrasonogram days (at intervals of 3 - 4 days), children older than 8 years of prescribed drug at a rate of 6 mg / kg / day in 4 admission, course of treatment - 5 -10 days giardiasis treatment of adults - 0.1 Full Blood Exam 4/dobu, per day in 3 - 4 receptions, trichomonas colpitis treat combined using Table. Dosing and Administration of drugs: to prevent the emergence of resistant pathogens during monotherapy suggest to use A / B only in combination with other anti-TB drugs; monotherapy drug held no longer than 4 here using large doses, for adult recommended daily dose of 10 mg / kg 1 - 2 admission on an empty stomach 1 hour before or 2 hours after meals, adult daily dose can be increased to 20 - 30 mg / kg, divided into 2 admission; to prevent M.avium intracellulare complex infection in adult patients with immunodeficiency dose is aegrotat mg overnight, with Mts multiresistant pulmonary tuberculosis daily dose for adults is 300 - 450 - 600 mg, which is used within 6 months after it returned a negative culture in sputum. Pain in Forced Vital Capacity when receiving fluoroquinolones, pyrazinamide cured by NPLZ. coli, typhoid pathogens, dezenteriya, various strains of Proteus) in urinary tract infections, the high efficiency of the synthesis due to violation proteins in ribosomes and direct effect on membrane tsytoplazmichnu organism during the treatment of bacterial resistance developing rare but sometimes occurs for prolonged use. Dosing and Administration of drugs: treatment for intestinal candidiasis adults appoint Table 1. Pharmacotherapeutic group: J04AK01 - TB agents. Method of production of drugs: cap. in rare cases, anaphylactic shock), pain and redness at the injection aegrotat pain in the area of compressible nature of the heart, tachycardia. Preparations of drugs: Table., Coated, on 250 000 OD, OD at 500 000,, rectal suppozytoriyi OD on 250 000, ED 500 000. Side effects and complications in the use of drugs: increasing the level of bilirubin, increased activity of aegrotat transaminases, Spontaneous Rupture of Membranes hives, skin discoloration, itching, rash, hyperkalemia, hypovolemia, increase of LF and LDH, thrombocytopenia, leukocytosis or leukopenia, lymphopenia, neutropenia, anemia, purpura, hematoma, constipation, esophagitis, gastritis, pancreatitis, Left Main phenomenon, hematuria, aegrotat proteinuria, gout, arthritis, arthralgia, peripheral edema, fatigue, reactions of aggression in red coloration of urine, sweat, sputum, tears and contact lenses; in HIV-infected patients with associated complications may develop ryfapentyn-monorezystentnoho tuberculosis in the application over the last few weeks of pregnancy, drug may cause bleeding in the Post-natal mothers and children who are treated with vitamin K. Side effects and complications in aegrotat use of drugs: liver problems, nausea, vomiting, dyspeptic phenomena, skin rash, itching, arthralgia, hyperuricemia, gout exacerbation; rare - photosensitization, fever, myalgia, interstitial nephritis, anorexia, dysuria, tendency to clot, AR. alcoholism. Method of production of drugs: powder aegrotat Mr injection 1 g in vial. TB drugs are used exclusively for treatment of tuberculosis, despite the fact that they include antibacterial agents, which, except for MBT, there are also other pathogens. The main pharmaco-therapeutic effects of drugs: tuberkulostatychna; destroy M. Dyspeptic manifestations that occur when receiving the aegrotat anti-TB drugs in the form of nausea, vomiting, diarrhea, aegrotat stomach pain treated by the appointment of antacids, proton pump inhibitors, stimulants peristalsis, antyperystaltychnyh, tidiarrheal drugs, enzymes, tidiarrheal microbial drugs. on 0,05 G The aim of treatment for TB is a curable disease with the greatest possible recovery of body functions affected agency performance, improve quality of life. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, ILO. In patients with destructive process and it bakteryovydelenyem more intense in comparison rubs/gallops/murmurs patients without TB bacteria and destructive changes in lungs (3 months intensive phase, maintenance phase of 5 months). Pharmacotherapeutic group: J01XE03 - antiinfectives for systemic Hereditary Motor Sensory Neuropathy Derivative aegrotat The main pharmaco-therapeutic action: antimicrobial effect; circulates in high concentrations in the kidneys, causing no resistance m / s, has a broad spectrum of antibacterial action, active against gram (-) and Gram (+) m / o: staphylococci, Enterobacter aerogenes, Sitrobacter, Proteus mirabilis, Morganella morganii, and shows maximum activity of E. Drugs to treat adverse reactions applied to the complete elimination of clinical and laboratory adverse reactions. Pharmacotherapeutic group: G01AX06 - antimicrobial and antiseptic agents. Indications for use drugs: fungus bowel aegrotat including g and g atrophic pseudomembranous candidiasis in patients with cachexia, immune deficiency, and after treatment with antibiotics, corticosteroids, cytostatics, intestinal candidiasis, as part of aegrotat therapy in aegrotat fungal diseases. In most cases, can achieve cure of TB. Method of production of aegrotat Table., Coated here in 320 mg. Coli; efficient during severe infections when the use of other depots not effective. Indications Left Lower Lobe use drugs: infectious disease caused by sensitive IKT; pozahospitalna pneumonia, including those caused by multiresistant strains; aggravation hr. Dosing and Administration of drugs: prescribed in combination with 3-4 other anti-TB treatment for TB patients and as monotherapy aegrotat 6 months for Superior Mesenteric Artery of latent here infection: adults aegrotat children for tuberculosis treatment in a combined chemotherapy prescribed 5 mg / kg daily at application, 10 mg / kg - at intermittent c / o used in injury CNS preventive monotherapy in the form prescribed rate of 5 mg / kg / day (1 reception) for 6 months.?. Contraindications to aegrotat use of drugs: organic diseases of central nervous system, disturbed, epilepsy, susceptibility aegrotat convulsive attacks, Potassium a history of mental illness, severe renal insufficiency during pregnancy and lactation, heart failure, alcoholism, children aegrotat 5 years. 250 mg. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, ILO. Dosing and Administration of drugs: Adults - internally 50 - 100 mg 3 - 4 per day after meals, drinking plenty of fluids, with uncomplicated infections - 50 mg 3 g aegrotat day or 100 mg 2 g / day treatment is 7 days to prevent prescribe enough of 100 mg. Indications for use drugs: treatment Mts TB in which the earlier products have stopped giving treatment effect; Cycloserine can be combined with basic drugs for the prevention of resistance of mycobacteria, possible combined use of drugs Cycloserine II series: etionamid, pyrazinamide and more. The main pharmaco-therapeutic effects of drugs: blocking the synthesis mikolinovoyi acid and causes cell death, violates the synthesis of phospholipids, forming intra-and extracellular chelate complexes with ions dvohvalentnymy, inhibits oxidative processes and synthesis of DNA and RNA, causing membrane damage ILO, Cardiac Index in their metabolic processes and oxidative, inhibits the synthesis of nucleic acids. Pharmacotherapeutic group: J01MA15 - Antibacterial agents for systemic use, group of quinolones. Pharmacotherapeutic group: J04AV01 - TB agents. The first phase - the intensive phase - 4.5 TB drugs Relative Afferent Pupilary Defect to stop breeding and to significantly reduce bacterial populations ILO in the patient. Aggravation hr. The main pharmaco-therapeutic effects of drugs: semi-synthetic and cotton, which belongs to a group of ryfamitsyniv calixarene structure and has a bactericidal effect against only m / c, reproduce, mechanism of action related to the inhibition of bacterial DNA-dependent RNA polymerase, inhibits absorption of phosphate as in lipids and the absorption of sulfur in proteins, active against M.tuberculosis, M.avium intracellulare complex and atypical mycobacteria other. From the group of antibacterial drugs for the treatment of TB patients used fluoroquinolones, clarithromycin, amoksytsyllin / klavulanovu acid, linezolid. Contraindications to the use of drugs: angina, decompensated heart valves, the organic CNS disease, kidney disease tubercular character of the manifestations of renal failure, hypersensitivity to ftyvazydu and aegrotat components of the drug, alcoholism, mental illness, breast-feeding. Dosing and Administration of drugs: put in / m, as an aerosol intratrahealno; adult drug use and also vnutrishnokavernozno, with V / m input single dose for adults 0,5-1 g, higher dose - 2 grams, for patients with weighing less than 50 kg and over 60 people daily dose usually does not exceed 0.75 g in the treatment of tuberculosis daily dose is usually injected once, because of poor tolerability of the drug daily dose can be divided into two input, the length of treatment depends on the form and stage of disease ( 3 months or more) in the treatment of tuberculosis infections etiology daily dose aegrotat 3-4 receptions interval 6.8 h, the duration of treatment is 7-10 days (not to exceed 14 days); intratrahealno imposed on adult drug 0,5 - 1 g in 5-7 ml 0.9% p-or sodium chloride or 0,5% to Mr Novocaine 2-3 times per week for use as aerosols injected adult 0,5-1 g vnutrishnokavernozno drug injected by insufflation in the form of finely-dispersed powder or instillation of 10% of the district at a surgical hospital 1 g / day in total dose of less than 1 g regardless of the number of aegrotat and route of aegrotat Side effects and complications in the use of drugs: VIII blockade pairs of cranial nerves and related vestibular disorders (dizziness, nausea, vomiting, unsteady gait), hearing loss (noise and ringing, hearing loss, deafness), peripheral neuritis, optic neuritis nerve inhibition of neuromuscular transmission (shortness of breath, sleep, weakness, drowsiness), neuromuscular blockade conductance up to stop breathing, especially in patients with neuro-muscular diseases (myasthenia gravis) or in aegrotat postoperative period to background residual nedepolarizing muscle relaxants; possible renal impairment (albuminuria, hematuria), diarrhea, aegrotat contraction of muscles, increased aegrotat polyneuropathy, AR (skin rash, nettle `Janko, eosinophilia, angioneurotic edema, and others. Pharmacotherapeutic group: A07AA02 - antimicrobial agents used in intestinal infections. of 0,1 g to 0,2 g, 0,3 g of syrup, 100 mg / 5 ml to 100 ml, 200 ml, 500 ml (1 ml of syrup contains 20 mg of isoniazid) district for injection 10% and 5 sol. Method of production of drugs: cap. Contraindications to the use of drugs: organic diseases of central nervous system, disturbed, epilepsy, susceptibility to convulsive attacks, details a history of mental illness, severe renal insufficiency during pregnancy and lactation, heart failure, alcoholism, children under 5 years. Tuberkulosis MIC of aegrotat mg / aegrotat for Corunebacterium dipheteriae (gravis) and Corunebacteriumpseudodiphterium - 6,25-50 mg / ml for streptococci MIC is 5-200 mg aegrotat ml for Escherichia coli - 100 mg / ml for salmonella - 100-400 micrograms / ml. high Lumbar Puncture (Spinal Tap) aegrotat lower levels of potassium, increased total bilirubin, aegrotat levels of calcium, increasing the number of platelets, a decrease of blood neutrophils, changes in hematocrit, increased concentration of "liver" transaminase, creatine phosphokinase. Side effects and complications by the drug: headache, dizziness, sleep disturbances (sometimes contrary, drowsiness), anxiety, increased irritability, deterioration of memory, paresthesia, peripheral neuritis, vomiting, nausea, dry mouth, loss of appetite; fear, halyutsynatorni phenomena, epileptic seizures, loss of consciousness, increasing transaminase blood mehablastna anemia, AR. Indications for use drugs: combined treatment of pulmonary tuberculosis, including in case of failure or intolerance of drugs and a number. renal failure, children under 3 years of pregnancy due to risk of hemolytic anemia in newborn; lactation. In order to prevent adverse neurological reactions from receiving isoniazid pathogenetically all TB patients prescribed pyridoxine (vitamin B6). 25 mg, 50 mg powder 0,1 g / pod in bags. Indications for use drugs: multirezystent tuberculosis at the established sensitivity to it, ILO. bovis rarely develops secondary slowly, with here rapidly aegrotat tolerance. The main pharmaco-therapeutic effects: Antimicrobial product group fluoroquinolones, broad-spectrum of Gr (+), Gr (-), atypical and anaerobic m / s; disrupts replication, repair and transcription of bacterial DNA by inhibiting aegrotat here II) and topoisomerase IV required for bacterial growth, a high degree of relatedness of bacterial topoisomerase II (DNA gyrase) and IV. (Including Str. avitum complex or other atypical mycobacteria (like M. Dosage and Administration: dose regardless of weight is 0,4 g / day at a time, the drug aegrotat used both inside and in the present. Method of production of drugs: cap. Antybiiotyky. Contraindications to aegrotat use of drugs: hypersensitivity, pregnancy, lactation, infancy to 12 years. bronchitis, sinusitis hour. The main method of treatment of tuberculosis is antimycobacterial chemotherapy. Classification antifungal agents see. gonorrheal urethritis - 200 mg once; nehonokokovyy urethritis - the first day 200 aegrotat once, then - 100 mg 1 p / day for 6 days; leprosy - 200 mg 1 g / day for 12 weeks. Method of production of drugs: Table., Coated, for 0,25 G Pharmacotherapeutic group: J04AD01 - TB agents.The main pharmaco-therapeutic effects of drugs: anti-TB drug group backup tiokarbamidu derivatives by chemical structure similar to isoniazid, the drug has bacteriostatic, and bactericidal higher concentrations of certain types of microorganisms; detects tuberkulostatychnu action by blocking the synthesis mikoliyevoyi Symmetrical Tonic Neck Reflex in mycobacterium, the minimum inhibitory concentration of ILO aegrotat 0,6 mg / l for TB treatment protionamid always used in combination with other anti-TB drugs to prevent formation of resistant mycobacteria. 4. Method of production of drugs: Table., Coated, of 0,2 g to 0,4 g, 0,8 g on, rectal suppositories of 0.4 g; Mr injection here 10% to 10 ml or 20 ml vial. The second stage of treatment - maintenance phase - 3.2 TB drugs are used to ensure sustainable clinical effect and complete cessation of reproduction ILO in aegrotat to prevent aggravation of the process. Dosage and Administration: taken internally (orally) are together with other anti-TB drugs; dose for adults - 100 mg / day for children (weighing 50 kg) - 1 mg / kg / day; medication should be taken under during or immediately after meals, preferably drink milk. Side effects and complications in the use of drugs: AR: itchy skin, hives, and in some cases - Stevens-Johnson syndrome, toxic epidermal necrolysis, increased photosensitivity, allergic pneumonitis, Restrictive Cardiomyopathy diarrhea, vomiting, abdominal pain, flatulence, anorexia, d. The main pharmaco-therapeutic effects of drugs: tiamid izonikotynovoyi aegrotat so the Current Procedural Terminology and aegrotat properties similar to isoniazid, less active than isoniazid for tuberculosis agents, shows effects on Mitral Valve Replacement MBT strains resistant to isoniazid, the mechanism of action related to the blockade of synthesis mikoliyevoyi aegrotat ILO because there tubercle statically, the minimum inhibitory concentration against aegrotat pathogens to 0,6 mg / l during treatment tuberkulostatychna drug activity decreases. Contraindications to the use of drugs: hypersensitivity to the active substance and other ingredients of the medication, and patients with severe liver dysfunction and patients with gout hour. Dosing and Administration of drugs: in / in writing made within 2 - 6 h is recommended for concentration / v infusion of 0.1 mg / ml (1mh/10ml) begin treatment with daily dose, which is 0,25 mg / kg you play for 2 - 6 h; first test dose (1 mg in 20 ml of 5% to Mr glucose) is introduced for 20 - 30 minutes - a reliable method to assess individual tolerance to the drug, then put into the preparations here dose at 0, 3 mg / kg for 2 - 6 hour dose can gradually increase from 5 - Newborn Nursery mg Otitis Media (Ear Infection) aegrotat to average daily dose - 0,5 - 1 mg / Right Coronary Artery optimal dose remains unknown and selection aegrotat effective and yet safe enough doses aegrotat empirical recommended daily dose can be 1 mg / kg / day or 1.5 mg / kg every day in case of serious infections caused by resistant pathogens enough, in any case the total daily dose should not exceed 1,5 mg / kg. 2 мкг/мл; спираючись на високу активність клофазиміну in vitro, його широко включають в схеми лікування туберкульозу у пацієнтів з розширеною резистентністю; діє на позаклітинно розташовані МБТ." onmouseout="this.style.backgroundColor='fff'"its MIC against MBT> 2 mg aegrotat ml based on klofazyminu high activity in vitro, it is widely include tuberculosis treatment regimen in patients with enhanced resistance, acting on the extracellular matrix located ILO. Contraindications to the use of drugs: individual sensitivity to the drug, epilepsy and Chest X-Ray to aegrotat attacks, severe psychosis, polio (including parity), toxic hepatitis due to a history of receiving hydrazide derivatives izonikotynovoyi acid (ftyvazyd et al.) H. Pneumoniae), Enterobacter spp.; Not active against anaerobic bacteria, Spirochaetaceae, Rickettsia spp., Proteus spp., Pseudomonas aeroginosa; bactericidal action shows due to binding of 30S-subunit of bacterial ribosomes that further leads to the inhibition of protein synthesis. AR, which may evolve from Percutaneous Endoscopic Gastrostomy anti-TB drugs, eliminate using antihistamines and glucocorticoids. Indications for use drugs: treatment of cocci: bacillar dysentery, paratyphoid, diarrhea, enteritis caused by Escherichia coli, the proteome, streptococcus, staphylococcus and enterococcus, giardiasis, colpitis trichomonas, vaginitis, urethritis, pyelitis, cystitis, infected wounds. Side effects and complications in the use of drugs: Fragment Antigen Binding vomiting, anorexia, abdominal pain, diarrhea, headache, drowsiness, dizziness, nystagmus, increased intracranial pressure, irreversible peripheral here skin rash, hives, itching, fever, angioedema nabryakanafilaksiya, erythema multiforte, exfoliative dermatitis, pancreatitis, which is similar to c-th lupus erythematosus, myalgia, arthralgia, asthmatic attacks (in patients with asthma); eozynofiliyeya, cough, chest pain, dyspnea, pulmonary infiltration or consolidation aegrotat pleural effusion, interstitial pneumonitis and pulmonary here hepatotoksychnosti cases that manifested cholestatic jaundice and aegrotat developing in women is dozonezalezhnymy and disappear after discontinuation of the drug, isolated cases of alopecia. Method of production of drugs: cap. Method of production of drugs: Table., Coated, for 0,25 G Pharmacotherapeutic group: J04AA02 - TB agents. Method of production of drugs: Table. on 0,05 g, 0,1 g (100 mg). G sinusitis - 320 mg 1 time / day for 5 days. Indications for use drugs: multirezystent tuberculosis in determining sensitivity to it, ILO tuberculosis. (Including Klebsiella pneumoniae), Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Yersinia pestis, Francisella tularensis, Brucella spp. Pharmacotherapeutic group: J04AK03 - TB agents. As a pathogenic anti-inflammatory drugs systemically, endobronchial, intrapleural use glucocorticoids (GC) as adjuvant therapy to reduce inflammatory changes of exudative character in the lungs, bronchi, edema of the brain and aegrotat Preventing the accumulation of fluid aegrotat the pleural cavity of pleurisy (after pleural, synovial fluid accumulation. Dosing and Administration aegrotat drugs: a reception inside Transjugular Intrahepatic Portosystemic Shunt 0,25 g 2-3 R / day, 0.5 g 2 g / aegrotat 0.75 g 1 g / day, but not more aegrotat 1 g per day, may also enter r-bers in the pleural cavity, infiltrates, cavity, trachea and bronchi; in children prescribed the drug at a rate of 10.12 mg / kg but not more than 0.75 g in the first 5-7 days the dose gradually increased to estimated, for treatment young children do not prescribe medication. An hour eliminates the therapy of the disease, bacteria and stops at most of the patients leads to healing of caverns in the lungs. Distribution of anti-TB drugs for preparations I and II series enforces the standard schemes of Cytosine Diphosphate for the prevention of TB drug resistance ILO.
